Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 77 of 110 Updated Nov 17, 2026

5-Amino-1MQ

5-amino-1-methylquinolinium

PRECLINICAL + ANECDOTAL · NNMT INHIBITOR SMALL MOLECULE

▓ 17 indexed citations across PubMed (2), EuropePMC (15).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

17 citations across 2 tiers

Tap any tier to jump to that section of the bibliography.

Mechanism of action

Inhibits nicotinamide N-methyltransferase (NNMT); raises intracellular NAD+ and SAM

Researched effects

NNMT inhibition; raises NAD+/SAM; fat metabolism; anti-obesity in mice

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

50-150 mg oral daily (anecdotal)

Known concerns

Human data very limited; no long-term safety

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Nicotinamide N-Methyltransferase in Cardiovascular Diseases: Metabolic Regulator and Emerging Therapeutic Target.

    2025 — RESEARCH ARTICLES · AUTHORITY 34.5

  2. Nicotinamide N-Methyltransferase in the Inflammatory Pathogenesis of Graves' Orbitopathy.

    2025 — RESEARCH ARTICLES · AUTHORITY 34.5

  3. Mechanism and kinetics of turnover inhibitors of nicotinamide N-methyl transferase in vitro and in vivo.

    2025 — RESEARCH ARTICLES · AUTHORITY 34.5

  4. Nicotinamide N-Methyltransferase (NNMT) and Liver Cancer: From Metabolic Networks to Therapeutic Targets.

    2025 — RESEARCH ARTICLES · AUTHORITY 34.5

  5. Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome.

    2024 — RESEARCH ARTICLES · AUTHORITY 34.4

  6. Control of NAD<sup>+</sup> homeostasis by autophagic flux modulates mitochondrial and cardiac function.

    2024 — RESEARCH ARTICLES · AUTHORITY 34.4

  7. Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice.

    2024 — RESEARCH ARTICLES · AUTHORITY 34.4

  8. Nicotinamide N-methyltransferase and liver diseases.

    2023 — RESEARCH ARTICLES · AUTHORITY 34.3

  9. Nicotinamide N-Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy.

    2022 — RESEARCH ARTICLES · AUTHORITY 34.2

  10. Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.

    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2021 — RESEARCH ARTICLES · AUTHORITY 34.1

Full citation library

Year distribution

Research Articles

16
  1. 1.

    Akar S, Duran T, Azzawri AA, Koçak N, et al. · Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2021 · PMID 33645410

    The anti-proliferative effects of 5-methylquinolinium (5MQ) of nicotinamide N-methyltransferase (NNMT) have not been previously investigated on a cervical cancer cell line. NNMT is a metabolic enzyme that is correlated with tumour progression and metastasis. 5MQ is a small molecule inhibitor of NNMT. 0.1-500 μM of 5MQ was tested on the HeLa epithelial cervical cancer cell line. Cell viability was assessed with the MTT test.

  2. 2.

    Dimet-Wiley A, Wu Q, Wiley JT, Eswar A, et al. · Scientific reports · 2022 · PMID 35013352

    Treatment with a nicotinamide N-methyltransferase inhibitor (NNMTi; 5-amino-1-methylquinolinium) combined with low-fat diet (LD) promoted dramatic whole-body adiposity and weight loss in diet-induced obese (DIO) mice, rapidly normalizing these measures to age-matched lean animals, while LD switch alone was unable to restore these measures to age-matched controls in the same time frame. Since mouse microbiome profiles often highly correlate with body weight and fat composition, this study was des…

  3. 3.

    Jawaria, Zarlashat Y, Philippovich M, Dósa E. · 2025 · PMID 41008588

    Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, arising from complex interactions among metabolic, genetic, and environmental factors. Nicotinamide N-methyltransferase (NNMT) has recently emerged as a key metabolic regulator in CVD pathogenesis. By consuming nicotinamide and methyl groups, NNMT perturbs epigenetic, metabolic, and redox pathways that are critical for cardiovascular health. NNMT-mediated NAD<sup>+</sup> depletion impairs mitochondrial fun…

  4. 4.

    Cho D, Choi SH, Yoon JS, Ko J. · 2025 · PMID 40310625

    <h4>Purpose</h4>Nicotinamide N-methyltransferase (NNMT) has been implicated in inflammatory autoimmune disease pathogenesis, although its pro-inflammatory role in Graves' orbitopathy (GO) is unclear. Therefore, we investigated the influence and mechanisms of NNMT in GO inflammation.<h4>Methods</h4>We evaluated NNMT mRNA expression in GO and non-GO orbital tissues via reverse transcription-quantitative PCR analysis. A pro-inflammatory process was induced in primary cultured orbital fibroblasts vi…

  5. 5.

    Liu JR, Deng ZH, Zhu XJ, Zeng YR, Guan XX, Li JH. · 2021 · PMID 34368359

    Type 2 diabetes (T2D) is thought to be a complication of metabolic syndrome caused by disorders of energy utilization and storage and characterized by insulin resistance or deficiency of insulin secretion. Though the mechanism linking obesity to the development of T2D is complex and unintelligible, it is known that abnormal lipid metabolism and adipose tissue accumulation possibly play important roles in this process. Recently, nicotinamide N-methyltransferase (NNMT) has been emerging as a new m…

  6. 6.

    Li XY, Pi YN, Chen Y, Zhu Q, Xia BR. · 2022 · PMID 35756670

    Cancer cells typically exhibit a tightly regulated program of metabolic plasticity and epigenetic remodeling to meet the demand of uncontrolled cell proliferation. The metabolic-epigenetic axis has recently become an increasingly hot topic in carcinogenesis and offers new avenues for innovative and personalized cancer treatment strategies. Nicotinamide <i>N</i>-methyltransferase (NNMT) is a metabolic enzyme involved in controlling methylation potential, impacting DNA and histone epigenetic modif…

  7. 7.

    Neelakantan H, Vance V, Wetzel MD, Wang HL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ. · 2018 · PMID 29155147

    There is a critical need for new mechanism-of-action drugs that reduce the burden of obesity and associated chronic metabolic comorbidities. A potentially novel target to treat obesity and type 2 diabetes is nicotinamide-N-methyltransferase (NNMT), a cytosolic enzyme with newly identified roles in cellular metabolism and energy homeostasis. To validate NNMT as an anti-obesity drug target, we investigated the permeability, selectivity, mechanistic, and physiological properties of a series of smal…

  8. 8.

    Sun WD, Zhu XJ, Li JJ, Mei YZ, Li WS, Li JH. · 2024 · PMID 38919254

    Metabolic syndrome (MetS) represents a constellation of metabolic abnormalities, typified by obesity, hypertension, hyperglycemia, and hyperlipidemia. It stems from intricate dysregulations in metabolic pathways governing energy and substrate metabolism. While comprehending the precise etiological mechanisms of MetS remains challenging, evidence underscores the pivotal roles of aberrations in lipid metabolism and insulin resistance (IR) in its pathogenesis. Notably, nicotinamide N-methyltransfer…

  9. 9.

    Zhang Q, Li Z, Li Q, Trammell SA, Schmidt MS, Pires KM, Cai J, Zhang Y, Kenny H, Boudina S, Brenner C, Abel ED. · 2024 · PMID 38212381

    Impaired autophagy is known to cause mitochondrial dysfunction and heart failure, in part due to altered mitophagy and protein quality control. However, whether additional mechanisms are involved in the development of mitochondrial dysfunction and heart failure in the setting of deficient autophagic flux remains poorly explored. Here, we show that impaired autophagic flux reduces nicotinamide adenine dinucleotide (NAD<sup>+</sup>) availability in cardiomyocytes. NAD<sup>+</sup> deficiency upon a…

  10. 10.

    Sampson CM, Dimet AL, Neelakantan H, Ogunseye KO, Stevenson HL, Hommel JD, Watowich SJ. · 2021 · PMID 33707534

    Obesity is a large and growing global health problem with few effective therapies. The present study investigated metabolic and physiological benefits of nicotinamide N-methyltransferase inhibitor (NNMTi) treatment combined with a lean diet substitution in diet-induced obese mice. NNMTi treatment combined with lean diet substitution accelerated and improved body weight and fat loss, increased whole-body lean mass to body weight ratio, reduced liver and epididymal white adipose tissue weights, de…

  11. 11.

    Akerud T, De Fusco C, Brandt P, Bergström F, Johansson P, Ek M, Börjesson U, Johansson A, Danielsson J, Bauer M, Arnaud B, Castaldo M, Strömstedt M, Rosengren B, Jansen F, Fredlund L. · 2025 · PMID 40209950

    Nicotinamide N-methyl transferase (NNMT) is involved in the regulation of cellular nicotinamide adenine dinucleotide (NAD) and S-adenosyl-L-methionine (SAM) levels and has been implicated in a range of human diseases. Herein, we show that a class of NNMT inhibitors, analogs of the natural substrate nicotinamide (NAM), is turned over by the enzyme and that the methylated product is a potent inhibitor of the enzyme. The product inhibitor is, however, charged and has modest cellular potency. Utiliz…

  12. 12.

    Iyamu ID, Huang R. · 2021 · PMID 34458733

    Nicotinamide <i>N</i>-methyltransferase (NNMT) plays an important role in diverse biological processes by regulating methylation potential and the degradation of nicotinamide. Meanwhile, the aberrant expression of NNMT has been implicated in multiple cancers, metabolic and liver diseases. Therefore, there has been an emerging interest in assessing NNMT as a potential therapeutic target and discovering NNMT inhibitors over the past 5 years. Herein, we focus on the recognition, mechanism, and inhi…

  13. 13.

    Liang G, Li Y, Lin Y, Yang X, Yang J, Hu S, Liu A. · 2023 · PMID 37492717

    Cellular metabolism-induced epigenetic regulation is essential for the maintenance of cellular homeostasis. Nicotinamide N-methyltransferase (NNMT) is emerging as a key point of intersection between cellular metabolism and epigenetic regulation and has a central role in various physiological and pathological processes. NNMT catalyzes the methylation of nicotinamide (NAM) using the universal methyl donor S-adenosyl methionine (SAM) to yield S-adeno-syl-L-homocysteine (SAH) and N1-methylnicotinami…

  14. 14.

    Lai SY, Zhu XJ, Sun WD, Bi SZ, Zhang CY, Liu A, Li JH. · 2025 · PMID 40427612

    Hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, remains a global health challenge with limited therapeutic options and high mortality rates. Despite advances in understanding its molecular pathogenesis, the role of metabolic reprogramming in HCC progression and therapy resistance demands further exploration. Nicotinamide N-methyltransferase (NNMT), a metabolic enzyme central to NAD<sup>+</sup> and methionine cycles, has emerged as a critical regulator of tumorigenes…

  15. 15.

    Dimet-Wiley AL, Latham CM, Brightwell CR, Neelakantan H, Keeble AR, Thomas NT, Noehren H, Fry CS, Watowich SJ. · 2024 · PMID 38969654

    Human hallmarks of sarcopenia include muscle weakness and a blunted response to exercise. Nicotinamide N-methyltransferase inhibitors (NNMTis) increase strength and promote the regenerative capacity of aged muscle, thus offering a promising treatment for sarcopenia. Since human hallmarks of sarcopenia are recapitulated in aged (24-month-old) mice, we treated mice from 22 to 24 months of age with NNMTi, intensive exercise, or a combination of both, and compared skeletal muscle adaptations, includ…

  16. 16.

    Neelakantan H, Brightwell CR, Graber TG, Maroto R, Wang HL, McHardy SF, Papaconstantinou J, Fry CS, Watowich SJ. · 2019 · PMID 30753815

    Aging is accompanied by progressive declines in skeletal muscle mass and strength and impaired regenerative capacity, predisposing older adults to debilitating age-related muscle deteriorations and severe morbidity. Muscle stem cells (muSCs) that proliferate, differentiate to fusion-competent myoblasts, and facilitate muscle regeneration are increasingly dysfunctional upon aging, impairing muscle recovery after injury. While regulators of muSC activity can offer novel therapeutics to improve rec…

Preprints (not yet peer-reviewed)

1
  1. 17.

    Chanvillard L, Lantermans H, Wall C, Thevenet J, Butter L, Tauzin L, Claessen N, Christen S, Karaz S, Lassueur S, Lizzo G, Sanchez-Garcia JL, Métairon S, Holzwarth JA, Ferro V, Moco S, van Bommel EJ, van Baar MJ, Hesp AC, van Raalte DH, Roelofs JJ, Sanders MJ, Feige JN, Sorrentino V, Tammaro A. · 2025

    <h4>ABSTRACT</h4> Chronic kidney disease (CKD) is a major global health issue, projected to become the fifth leading cause of mortality by 2040. Renal tubular cell senescence is a key driver of kidney fibrosis, the final manifestation of CKD. However, current treatment strategies, do not target senescent cells, as the underlying mechanisms driving this dysfunctional phenotype remain poorly described. Here, we identify nicotinamide-N-methyltransferase (NNMT), as a critical mediator of tubular sen…

Curated sources on file

1
  1. 1.

Continue reading